microdosing glp-1 inflammation The People v. GLP-1's Let’s talk GLP-1s & microdosing

Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe

The FDA decision is anticipated in 3Q2025

Children: Wegovy can be used for weight loss in children ages 12 years and older with obesity

Lotte Bjerre Knudsen (43:30): I think we've been around all the exciting biology of GLP-1, both in diabetes, obesity, cardiovascular, kidney, potential in Alzheimer's and addiction

The latest data confirms that this effect is now material at a market level

One innovative therapy we offer is the Ozempic shot, a GLP-1 receptor agonist originally developed to manage type 2 diabetes and now widely recognized for its remarkable effectiveness in promoting weight loss